XML 43 R16.htm IDEA: XBRL DOCUMENT

Contract Research and Development Revenue and Miscellaneous Income	12 Months Ended
Dec. 31, 2011
Contract Research And Development Revenue And Miscellaneous Income [Text Block]	(10) Contract Research and Development Revenue and Miscellaneous Income Contract research and development is specific to the transition services agreement the Company entered into with the purchaser of the specialty pharmaceutical business. The transition services agreement was initiated in January 2010 at the time of the sale. It provides for a reimbursement for services provided by the Company plus a mark-up and totaled $1.4 million and $9.3 million in 2011 and 2010, respectively. These services could continue for up to three years after the sale, but diminished significantly during the course 2011. Miscellaneous income includes income received pursuant to the transition services agreement related to general and administrative support to the purchaser of the specialty pharmaceutical business and sublease revenues received by the Company from tenants under terms of sublease agreements. These transitional services were minimal in 2011 ($0.1 million) versus 2010 ($2.4 million) as the term of the agreement for other than research and development support activities was approximately one year from January 2010. Sublease revenues of $0.6 million and $0.3 million for 2011 and 2010, respectively, relate to the Company’s leased facility in South Plainfield, New Jersey, which commenced in 2009 and runs through October 2012, and excess leased office space in Bridgewater, New Jersey, which commenced in 2011 as a result of the first quarter relocation to Piscataway, New Jersey and will continue through January 2013 (see Note 20, Leases).

Contract Research and Development Revenue and Miscellaneous Income

12 Months Ended

Dec. 31, 2011

Contract Research And Development Revenue And Miscellaneous Income [Text Block]

(10) Contract Research and Development Revenue and Miscellaneous Income

Contract research and development is specific to the transition services agreement the Company entered into with the purchaser of the specialty pharmaceutical business. The transition services agreement was initiated in January 2010 at the time of the sale. It provides for a reimbursement for services provided by the Company plus a mark-up and totaled $1.4 million and $9.3 million in 2011 and 2010, respectively. These services could continue for up to three years after the sale, but diminished significantly during the course 2011.

Miscellaneous income includes income received pursuant to the transition services agreement related to general and administrative support to the purchaser of the specialty pharmaceutical business and sublease revenues received by the Company from tenants under terms of sublease agreements. These transitional services were minimal in 2011 ($0.1 million) versus 2010 ($2.4 million) as the term of the agreement for other than research and development support activities was approximately one year from January 2010. Sublease revenues of $0.6 million and $0.3 million for 2011 and 2010, respectively, relate to the Company’s leased facility in South Plainfield, New Jersey, which commenced in 2009 and runs through October 2012, and excess leased office space in Bridgewater, New Jersey, which commenced in 2011 as a result of the first quarter relocation to Piscataway, New Jersey and will continue through January 2013 (see Note 20, Leases).